Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Antiviral Res. 2016 Nov 24;137:165–172. doi: 10.1016/j.antiviral.2016.11.017

Fig. 2. Synergistic inhibition of infection of Ebola live virus in Vero E6 cells by three-drug combinations.

Fig. 2

(A) Confirmatory dose-response curves of toremifene (dark line), mefloquine (blue line), posaconazole (green line), and clarithromycin (purple line) in inhibiting EBOV in Vero E6 cells using eGFP-EBOV assay. (B-D) Synergistic inhibition of EBOV infection by three-drug combination: TCP (0.15 μM toremifene, 2 μ M clarithromycin and 4 μM posaconazole), TMP (0.15 μM toremifene, 2 μM mefloquine and 4 μM posaconazole), and CMA (2 μ M chloroquine, 1 μM maprotiline and 1 μM azithromycin). All experiments were performed in triplicate and data are representative of at least two independent experiments. Data are represented as mean±s.e.m. For B, C and D, ***P ≤ 0.001. ns = difference is not statistically significant. P value indicates that the statistical significance was measured by Student’s t-test.